Amgen tightens 340B program rules, expanding pharmacy claims data requirements

Amgen announced it is expanding the data it requires from pharmacies that dispense its products under the federal 340B drug discount program.

The new policy will obligate participating pharmacies to submit more detailed claims information, which the company says is intended to address what it describes as fraud and misuse of the program.

Amgen indicated the changes are meant to protect the integrity of 340B and ensure discounts are applied correctly, though the added reporting burden may affect pharmacy operations.